CIPLA.BO Earnings — Cipla Limited
BSE
Updated
About Cipla Limited
Operating globally across India, the United States, South Africa, and other international markets, Cipla Limited, along with its affiliated entities, is engaged in the production, advancement, and distribution of pharmaceutical goods. Its operations are structured into two principal divisions: Pharmaceuticals and New Ventures. Beyond active pharmaceutical ingredients (APIs), the company delivers diverse formulations addressing a wide array of therapeutic areas. These encompass cardio-metabolic conditions (including treatments for MI, angina, heart failure, hypertension, arrhythmia, lipid abnormalities, diabetes, and obesity), HIV, respiratory disorders, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. Its specialized respiratory portfolio features inhalers and nasal sprays, complemented by other related offerings such as injectables and biosimilar treatments. A specific product noteworthy is Easylax and Easylax L, a liquid paraffin solution designed to alleviate constipation. Established in 1935, Cipla Limited maintains its corporate headquarters in Mumbai, India.
🤖 AI Earnings Analysis
CIPLA.BO’s 31.98× P/E alongside a 13.77% profit margin signals investors are paying a premium for moderately profitable earnings.
AI-generated summary — powered by BigEarnings.
Earnings History
No confirmed earnings data available yet.
Showing last 0 quarters.